Saturday 17 October 2026
Export PODD’s income statement to Excel — free account
Insulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
141.10
2.33
+1.68%
Follow PODD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
88.21 | 81.21 | 48.80 | 28.46 |
P/S ratio |
8.61 | 7.38 | 5.06 | 3.46 | |
P/FCF ratio |
53.31 | 57.15 | 37.87 | 39.72 | |
P/Operating CF |
172.83 | 109.09 | 129.05 | 119.35 | |
P/B ratio |
15.69 | 13.20 | 11.27 | 7.42 | |
Price to Tangible BV |
17.70 | 14.85 | 12.93 | 8.40 | |
EV/Sales |
8.72 | 7.47 | 5.22 | 3.59 | |
EV/EBITDA |
41.91 | 35.85 | 25.17 | 17.83 | |
EV/Operating CF |
41.20 | 35.53 | 24.47 | 21.45 | |
EV/FCF |
53.94 | 57.81 | 39.08 | 41.28 | |
Quick Ratio |
1.88 | 1.81 | 1.49 | 1.51 | |
Current Ratio |
2.87 | 2.81 | 2.49 | 2.48 | |
Net Debt/EBITDA |
1.84 | 1.37 | 3.15 | 2.64 | |
Debt/Assets |
33.50% | 29.75% | 31.74% | 29.96% | |
Debt/Equity |
0.73 | 0.63 | 0.73 | 0.67 | |
Asset Turnover |
0.83 | 0.86 | 0.89 | 0.92 | |
Operating CF/Net income |
1.43 | 1.80 | 1.25 | 0.93 | |
Capex/Depreciation |
(1.41) | (6.12) | (1.06) | (1.40) | |
Interest Coverage |
7.54 | 9.75 | 8.31 | 9.61 | |
Research and Development Expense of Revenue |
10.93% | 11.60% | 11.78% | 10.99% | |
Selling, General and Administrative Expense of Revenue |
44.63% | 42.29% | 41.64% | 43.01% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.06 | 0.05 | |
Share Based Compensation of Revenue |
2.36% | 2.59% | 2.80% | 2.44% | |
Graham Net Nets |
0.01 | 0.01 | 0.00 | 0.01 | |
Graham Number |
39.36 | 41.19 | 42.44 | 49.70 | |
Earnings Yield |
1.13% | 1.23% | 2.05% | 3.51% | |
Free Cash Flow Yield |
1.88% | 1.75% | 2.64% | 2.52% | |
Revenue per Share |
10.04 | 11.14 | 10.88 | 11.57 | |
Operating CF per Share |
1.79 | 2.61 | 1.63 | 1.28 | |
Capex per Share |
(0.44) | (2.12) | (0.40) | (0.54) | |
Free Cash Flow per Share |
1.34 | 0.48 | 1.23 | 0.74 | |
Cash per Share |
10.76 | 10.18 | 6.86 | 7.72 | |
Shareholders Equity per Share |
19.67 | 21.54 | 18.61 | 20.52 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
19.67 | 21.54 | 18.61 | 20.52 | |
Free Cash Flow |
94.60 | 33.90 | 86.00 | 51.10 | |
Working Capital |
1,211.70 | 1,233.90 | 1,022.00 | 1,104.90 | |
Capital Expenditures |
(31.10) | (149.40) | (27.80) | (37.30) | |
Net Current Asset Value |
214.30 | 238.80 | 24.90 | 106.20 | |
EV/EBIT |
50.30 | 42.69 | 29.88 | 21.26 | |
Capex to Sales |
0.04 | 0.19 | 0.04 | 0.05 | |
Price to Operating Income |
49.71 | 42.20 | 28.96 | 20.46 | |
| Other line items | |||||
Average Receivables |
418.90 | 441.20 | 473.50 | 516.60 | |
Average Payables |
44.25 | 47.40 | 103.70 | 109.70 | |
Average Inventory |
445.60 | 441.50 | 451.65 | 465.85 | |
Average Assets |
3,027.35 | 3,139.05 | 3,252.25 | 3,317.15 | |
Average Common Equity |
1,251.15 | 1,363.45 | 1,316.65 | 1,442.60 |
Columns are period end dates